Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
How I treat cytopenias after CAR T-cell therapy
Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …
[HTML][HTML] Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome
Background T cell mediated hyperinflammatory responses such as cytokine release
syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) are …
syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) are …
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
K Rejeski, A Perez, G Iacoboni, V Blumenberg… - Science …, 2023 - science.org
Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment
landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side …
landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side …
The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following …
Abstract CD19‐directed CAR T‐cell therapy with brexucabtagene autoleucel (brexu‐cel)
has substantially improved treatment outcomes for patients with relapsed/refractory mantle …
has substantially improved treatment outcomes for patients with relapsed/refractory mantle …
Toxicities following CAR-T therapy for hematological malignancies
R Hernani, A Benzaquén, C Solano - Cancer Treatment Reviews, 2022 - Elsevier
Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in patients with
relapsed/refractory hematological malignancies. Research is also extending to other …
relapsed/refractory hematological malignancies. Research is also extending to other …
[HTML][HTML] Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines …
Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …
[HTML][HTML] An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on …
Hematological toxicity represents the most common grade≥ 3 toxicity after chimeric antigen
receptor (CAR) T-cell therapy. However, its underlying pathophysiology is incompletely …
receptor (CAR) T-cell therapy. However, its underlying pathophysiology is incompletely …
[HTML][HTML] Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma
MS Hoffmann, BD Hunter, PW Cobb, JC Varela… - … and Cellular Therapy, 2023 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …